熱門資訊> 正文
Bionano Genomics因季度亏损收窄、收入超过预期而上涨7%
2024-05-09 04:54
- Bionano Genomics (NASDAQ:BNGO) is up 7% in after-hours trading Wednesday after reporting Q1 2024 results that showed its quarterly loss narrowed year over year and posting a revenue beat.
- The Q1 net loss of~ $31.4M compares to a ~$37.1M loss in the year-ago period.
- In the quarter, the company brought its total installed base of optical genome mapping (OGM) systems to 347, a 34% increase over Q1 2023.
- Bionano also sold 8,249 nanochannel array flowcells in the quarter, a 58% year-over-year increase over the number of flowcells sold in Q1 2023.
- Due to the expansion of cost savings initiatives announced in March, the company anticipates having reduced annualized non-GAAP operating expenses by about $65M-$75M by Q1 2025.
More on Bionano Genomics
- Bionano Genomics, Inc. (BNGO) Q4 2023 Earnings Call Transcript
- Bionano Genomics reports Q1 results
- Bionano announces $10M registered direct offering
- Seeking Alpha’s Quant Rating on Bionano Genomics
- Historical earnings data for Bionano Genomics
推薦文章
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
